These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 21549517)

  • 21. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.
    Kachnic LA; Shaw JE; Manning MA; Lauve AD; Neifeld JP
    Int J Cancer; 2001 Apr; 96(2):132-9. PubMed ID: 11291097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study.
    Bai YR; Wu GH; Guo WJ; Wu XD; Yao Y; Chen Y; Zhou RH; Lu DQ
    World J Gastroenterol; 2003 Nov; 9(11):2561-4. PubMed ID: 14606097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT.
    Gkika E; Adebahr S; Kirste S; Schimek-Jasch T; Wiehle R; Claus R; Wittel U; Nestle U; Baltas D; Grosu AL; Brunner TB
    Strahlenther Onkol; 2017 Jun; 193(6):433-443. PubMed ID: 28138949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
    Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
    Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
    Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis.
    Tchelebi LT; Lehrer EJ; Trifiletti DM; Sharma NK; Gusani NJ; Crane CH; Zaorsky NG
    Cancer; 2020 May; 126(10):2120-2131. PubMed ID: 32125712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
    Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.
    Dholakia AS; Chaudhry M; Leal JP; Chang DT; Raman SP; Hacker-Prietz A; Su Z; Pai J; Oteiza KE; Griffith ME; Wahl RL; Tryggestad E; Pawlik T; Laheru DA; Wolfgang CL; Koong AC; Herman JM
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):539-46. PubMed ID: 24751410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent chemoradiotherapy for advanced pancreatic cancer: 1,000 mg/m2 gemcitabine can be administered using limited-field radiotherapy.
    Yamazaki H; Nishiyama K; Koizumi M; Tanaka E; Ioka T; Uehara H; Iishi H; Nakaizumi A; Ohigashi H; Ishikawa O
    Strahlenther Onkol; 2007 Jun; 183(6):301-6. PubMed ID: 17520183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer.
    Rao AD; Sugar EA; Chang DT; Goodman KA; Hacker-Prietz A; Rosati LM; Columbo L; O'Reilly E; Fisher GA; Zheng L; Pai JS; Griffith ME; Laheru DA; Iacobuzio-Donahue CA; Wolfgang CL; Koong A; Herman JM
    Pract Radiat Oncol; 2016; 6(6):417-424. PubMed ID: 27552809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.
    Lin C; Verma V; Lazenby A; Ly QP; Berim LD; Schwarz JK; Madiyalakan M; Nicodemus CF; Hollingsworth MA; Meza JL; Are C; Padussis J; Grem JL
    Am J Clin Oncol; 2019 Oct; 42(10):755-760. PubMed ID: 31513018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
    Pipas JM; Mitchell SE; Barth RJ; Vera-Gimon R; Rathmann J; Meyer LP; Wagman RS; Lewis LD; McDonnell C; Colacchio TA; Perez RP
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1317-22. PubMed ID: 11483344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer.
    Small W; Mulcahy MF; Rademaker A; Bentrem DJ; Benson AB; Weitner BB; Talamonti MS
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):476-82. PubMed ID: 20598452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
    Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. External beam radiotherapy plus 24-hour continuous infusion of gemcitabine in unresectable pancreatic carcinoma: long-term results of a phase II study.
    Mattiucci GC; Morganti AG; Valentini V; Ippolito E; Alfieri S; Antinori A; Crucitti A; D'Agostino GR; Di Lullo L; Luzi S; Mantini G; Smaniotto D; Doglietto GB; Cellini N
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):831-8. PubMed ID: 19427747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
    Blackstock AW; Tepper JE; Niedwiecki D; Hollis DR; Mayer RJ; Tempero MA
    Int J Gastrointest Cancer; 2003; 34(2-3):107-16. PubMed ID: 15361643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
    Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
    Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
    Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer.
    Courtney PT; Paravati AJ; Atwood TF; Raja N; Zimmerman CT; Fanta PT; Lowy AM; Simpson DR; Xu R; Murphy JD
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1003-1012. PubMed ID: 33571625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stereotactic body radiotherapy (SBRT) for patients with locally advanced pancreatic cancer: A single center experience.
    Jumeau R; Delouya G; Roberge D; Donath D; Béliveau-Nadeau D; Campeau MP
    Dig Liver Dis; 2018 Apr; 50(4):396-400. PubMed ID: 29326012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.